144 related articles for article (PubMed ID: 29274441)
21. Ocular hypotensive effects of an intratracheally delivered liposomal delta9-tetrahydrocannabinol preparation in rats.
Szczesniak AM; Kelly ME; Whynot S; Shek PN; Hung O
J Ocul Pharmacol Ther; 2006 Jun; 22(3):160-7. PubMed ID: 16808676
[TBL] [Abstract][Full Text] [Related]
22. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
Ota T; Murata H; Sugimoto E; Aihara M; Araie M
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2006-11. PubMed ID: 15914616
[TBL] [Abstract][Full Text] [Related]
23. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring?
Scozzafava A; Menabuoni L; Mincione F; Briganti F; Mincione G; Supuran CT
J Med Chem; 1999 Jul; 42(14):2641-50. PubMed ID: 10411484
[TBL] [Abstract][Full Text] [Related]
24. Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications.
Johnson TV; Toris CB; Fan S; Camras CB
J Glaucoma; 2008 Mar; 17(2):89-99. PubMed ID: 18344753
[TBL] [Abstract][Full Text] [Related]
25. Preperimetric normal tension glaucoma study: long-term clinical course and effect of therapeutic lowering of intraocular pressure.
Jeong JH; Park KH; Jeoung JW; Kim DM
Acta Ophthalmol; 2014 May; 92(3):e185-93. PubMed ID: 24456145
[TBL] [Abstract][Full Text] [Related]
26. Analogs of the ATP-Sensitive Potassium (KATP) Channel Opener Cromakalim with in Vivo Ocular Hypotensive Activity.
Roy Chowdhury U; Viker KB; Stoltz KL; Holman BH; Fautsch MP; Dosa PI
J Med Chem; 2016 Jul; 59(13):6221-31. PubMed ID: 27367033
[TBL] [Abstract][Full Text] [Related]
27. Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.
Akaishi T; Shimazaki A; Tonouchi A; Ueda K; Miyawaki N; Kawazu K
J Ocul Pharmacol Ther; 2015 Nov; 31(9):518-24. PubMed ID: 26325164
[TBL] [Abstract][Full Text] [Related]
28. Ocular effects of topical 0.03% bimatoprost solution in normotensive feline eyes.
Regnier A; Lemagne C; Ponchet A; Cazalot G; Concordet D; Gelatt KN
Vet Ophthalmol; 2006; 9(1):39-43. PubMed ID: 16409244
[TBL] [Abstract][Full Text] [Related]
29. Ocular hypotensive effects of anti-glaucoma agents in mice.
Akaishi T; Odani-Kawabata N; Ishida N; Nakamura M
J Ocul Pharmacol Ther; 2009 Oct; 25(5):401-8. PubMed ID: 19857101
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives.
Ramprasad J; Nayak N; Dalimba U; Yogeeswari P; Sriram D; Peethambar SK; Achur R; Kumar HS
Eur J Med Chem; 2015 May; 95():49-63. PubMed ID: 25794789
[TBL] [Abstract][Full Text] [Related]
31. Influence of various concentrations of terpene-4-ol enhancer and carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits.
Afouna MI; Khedr A; Abdel-Naim AB; Al-Marzoqi A
J Pharm Sci; 2010 Jan; 99(1):119-27. PubMed ID: 19530071
[TBL] [Abstract][Full Text] [Related]
32. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
Prasanna G; Fortner J; Xiang C; Zhang E; Carreiro S; Anderson S; Sartnurak S; Wu G; Gukasyan H; Niesman M; Nair S; Rui E; Lafontaine J; Almaden CD; Wells P; Krauss A
Exp Eye Res; 2009 Nov; 89(5):608-17. PubMed ID: 19445930
[TBL] [Abstract][Full Text] [Related]
33. Derivatives of asparagic acid with hypotensive action.
Sunel V; Ciugureanu C; Ungureanu M
Rev Med Chir Soc Med Nat Iasi; 1996; 100(1-2):163-6. PubMed ID: 9455420
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
[TBL] [Abstract][Full Text] [Related]
35. Intraocular pressure lowering effects of novel arylpiperazine derivatives.
Chiang CH; Chang TJ; Lu DW; Lee AR
J Ocul Pharmacol Ther; 1998 Aug; 14(4):313-22. PubMed ID: 9715434
[TBL] [Abstract][Full Text] [Related]
36. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
Brandt JD; Beiser JA; Gordon MO; Kass MA;
Am J Ophthalmol; 2004 Nov; 138(5):717-22. PubMed ID: 15531304
[TBL] [Abstract][Full Text] [Related]
37. [Effects of pilocarpine in new ophthalmic formulations on intraocular pressure in rabbits with ocular hypertension].
Xu Y; Chen Z; Song J
Zhonghua Yan Ke Za Zhi; 2002 Dec; 38(12):721-4. PubMed ID: 12654220
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of angiotensin converting enzyme inhibitor-induced IOP reduction in normotensive rats.
Agarwal R; Krasilnikova AV; Raja IS; Agarwal P; Mohd Ismail N
Eur J Pharmacol; 2014 May; 730():8-13. PubMed ID: 24583339
[TBL] [Abstract][Full Text] [Related]
39. EFFECT OF HYDROGEN SULPHIDE DONOR ON INTRAOCULAR PRESSURE IN RATS.
Mikheytseva LN; Siroshtanenko TI
Fiziol Zh (1994); 2016; 62(5):57-61. PubMed ID: 30204343
[TBL] [Abstract][Full Text] [Related]
40. Effects of topical anandamides on intraocular pressure in normotensive rabbits.
Pate DW; Järvinen K; Urtti A; Jarho P; Fich M; Mahadevan V; Järvinen T
Life Sci; 1996; 58(21):1849-60. PubMed ID: 8637411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
